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CD40 ligand expression is defective in a subset of patients with
common variable immunodeficiency
(gp39/primary immunodeficiency syndrome)
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ABSTRACT Common variable immunodeficiency (CVI) is
characterized by hypogammaglobulinemia and recurrent bac-
terial infections due to failure of CVI B cells to differentiate in
vivo into immunoglobulin-secreting plasma cells. We hypoth-
esized that T-cell dysfunction resulting in abnormal contact-
mediated B-cell activation may play a prominent role in the
failure of CVI B cells to produce specific antibody. We have
previously shown that B-cell proliferation and IgE production
after stimulation with anti-CD40 and interleukin (IL) 4 were
normal in 22 CVI patients evaluated, indicating that CVI B
cells respond to signals delivered via CD40. Here we report that
CD40 ligand (gp39) mRNA expression by activated lympho-
cytes from CVI patients (n = 31) as a group was significantly
depressed (P < 0.0001) compared with normal controls (n =
32). gp39 mRNA expression by activated lymphocytes from 13
CVI patients fell below the normal control range. T-cell surface
expression of functional gp39 protein was correspondingly low
in those patients with gp39 mRNA levels below normal control
range and normal in patients with gp39 mRNA levels within
normal control range. In CVI patients as a group, gp39 mRNA
levels correlated with IL-2 mRNA levels (P < 0.002, r = 0.6)
and production (P < 0.001, r = 0.7) but not with gene
expression or production of other lymphokines evaluated,
suggesting an as-yet-undetermined association between gp39
and IL-2 gene regulation. Of the 13 patients whose activated T
cells exhibited gp39 mRNA expression below the normal con-
trol range, 2 had normal T-cell-derived lymphokine produc-
tion, whereas the remaining 11 exhibited broader T-cell dys-
function, resulting in IL-2 deficiency, and in some patients
deficient production of other lymphokines as well, reflecting a
heterogeneity in the underlying mechanisms leading to de-
pressed gp39 expression in these patients. The observation that
both gene and surface expression of gp39 by activated T cells
is depressed in a subgroup of CVI patients suggests that
inefficient signaling via CD40 may be responsible, in part, for
failure of B-cell differentiation in these patients.
Common variable immunodeficiency (CVI) is a heteroge-
neous group of disorders characterized by hypogammaglob-
ulinemia, antibody deficiency, and recurrent bacterial infec-
tions (1). Most CVI patients have normal numbers of circu-
lating T cells and surface immunoglobulin-positive B cells;
however, CVI B cells fail to differentiate into immunoglob-
ulin-secreting plasma cells in vivo (2-4). Consequently, CVI
patients have reduced levels of serum immunoglobulin and
respond abnormally to immunization with protein and poly-
saccharide antigens (5, 6). An intrinsic B-cell defect (3, 7, 8),
excessive T-suppressor activity (9-11), or defective T/B-cell
interaction (12-15) has been postulated as responsible for the
failure of CVI B-cell differentiation.
The finding that CVI B cells could proliferate and produce
immunoglobulin if appropriately stimulated in vitro (13, 16)
suggests that T-cell dysfunction resulting in depressed or
absent contact-mediated B-cell activation may be of impor-
tance for the failure of CVI B cells to differentiate into
immunoglobulin-producing plasma cells. It has been shown
in both murine and human systems that signals delivered via
the B-cell surface antigen CD40 play an important role in
B-cell proliferation, differentiation, and isotype switching
(17-19). Anti-CD40 monoclonal antibody (mAb) in synergy
with interleukin (IL) 4 induces B-cell proliferation (20, 21)
and IgE secretion (21-25) and in synergy with IL-10 induces
B cells to produce IgA, IgG, and IgM (16, 26). The recent
characterization (27-29) and cloning (30-32) of a 39-kDa
protein (gp39) on activated human T cells that binds CD40
and transduces a B-cell activation signal provided the oppor-
tunity to investigate the expression of gp39, on both mRNA
and protein levels, by activated T cells from patients with
primary immunodeficiency syndromes. As a result of these
investigations, we (33) and others (34-37) found that gp39
protein expressed by activated T cells from patients with X
chromosome-linked hyper-IgM syndrome (HIM) is function-
ally defective and that the gene encoding gp39 is located at
Xq2.6, the site where the gene responsible for HIM had been
previously mapped by family linkage studies (38), suggesting
that defective gp39 is the molecular defect directly respon-
sible for the inability of HIM B cells to switch from IgM to
other immunoglobulin isotypes. Further studies revealed that
anti-CD40 mAb could drive HIM B cells (33) and CVI B cells
(16) to proliferate in vitro and produce IgE if costimulated
with IL-4. These findings suggest that defective gp39 expres-
sion by activated T cells may also play a role in the antibody
deficiency observed in CVI patients. Using RNA blot anal-
ysis and CD40-immunoglobulin fusion protein binding ex-
periments, we found that gp39 expression by activated T cells
was depressed in CVI patients compared with normal con-
trols, suggesting that suboptimal gp39-CD40 interaction may
contribute to B-cell dysfunction in a subgroup of CVI pa-
tients.
MATERIALS AND METHODS
Patient Population. A total of 31 patients, 20 males and 11
females (12-77 yr of age, mean = 38 yr, median = 37 yr), with
well-documented CVI were included in the study. IgG, IgM,
Abbreviations: CVI, common variable immunodeficiency; mAb,
monoclonal antibody; IL, interleukin; HIM, X chromosome-linked
hyper-IgM syndrome; PHA, phytohemagglutinin; PMA, phorbol
12-myristate 13-acetate.
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and IgA levels were less than age-matched normal control
range in 31/31, 29/31, and 30/31 patients, respectively. All
patients exhibited abnormal antibody responses to several
recall antigens, including diphtheria/tetanus toxoid and
pneumococcal polysaccharides. The immune response to the
T-cell-dependent neoantigen bacteriophage 46X174 had been
evaluated in all 31 patients. Phage-specific antibody, of both
IgM and IgG isotypes, was significantly depressed in all
patients. The ability to switch from IgM to IgG during the
secondary immune response to bacteriophage was com-
pletely absent or abnormal (<20%o phage-specific IgG) in 21
patients and normal (>20%o phage specific IgG) in 11 patients.
Absolute lymphocyte count was normal in 18 patients and
decreased (<1100) in 13 patients. CD4/CD8 ratio was normal
in 22 patients and depressed (<0.75) in the remaining 9
patients. All but one patient received regular infusions of i.v.
immunoglobulin at 2- to 4-week intervals. Each patient was
studied at the maximum time interval after the last i.v.
immunoglobulin infusion to avoid possible effects of i.v.
immunoglobulin therapy on lymphocyte function. Healthy
blood donors (n = 32) served as controls and were studied in
parallel with each patient.
gp39 Gene Expression. Peripheral blood was collected in
preservative-free heparin, and peripheral blood mononuclear
cells were isolated by Ficoll/Hypaque density gradient cen-
trifugation. Peripheral blood mononuclear cells were cul-
tured at a final concentration of 5 x 106 cells per ml under
standard conditions (370C, 5% C02) in RPMI 1640 medium
(Sigma), containing 10% heat-inactivated fetal calf serum
(HyClone), 1 mM L-glutamine, penicillin at 100 units/ml, and
streptomycin at 100 pg/ml (GIBCO) for 6 hr in the presence
of phytohemaggluti (PHA) (final concentration, 3 pg/mIl)
(Wellcome) and phorbol 12-myristate 13-acetate (PMA; final
concentration, 10 ng/ml) (Sigma). Total cellular RNA was
isolated by the guanidinium thiocyanate/cesium chloride
method (39), and RNA blot analysis was done as described
(33). Human gp39 (30) and CD3 8-chain (40, 41) 32P-labeled
cDNA hybridization probes were prepared by using a com-
mercially available oligolabeling kit (Pharmacia).
mRNA levels were quantitated by densitometry and inte-
gration of autoradiograph bands (Bioimage Products version
4.1.1, Millipore). To correct for the amount ofT-cell message
on the blot, we divided the integrated OD for gp39 by the
integrated OD for CD38. For each blot, the corrected inte-
grated OD for gp39 was divided by the median of the
corrected integrated ODs of the normal controls. The gen-
erated value (with 1.0 representing the median of a normally
distributed population) allowed comparison of normal con-
trols and CVI patients from different blots.
CD40-Immunoglobuin Bindig Assays. Peripheral blood
mononuclear cells were isolated by centrifugation over lym-
phocyte separation medium (Organon Teknika-Cappel) and
washed twice in RPMI 1640 medium. Cells (107) were resus-
pended in 3 ml of RPMI 1640 medium/heat-inactivated 10%
fetal calf serum, with or without PMA (10 ng/ml) plus
ionomycin (1 Ag/ml) and incubated at 370C in 5% C02/95%
air for 8 hr. Cells were subsequently washed, resuspended in
RPMI 1640 medium/2% fetal calf serum/0.1% NaN3 (stain-
ing medium) and plated at 5 x 10W cells per well in a 96-well
microtiter plate. Cells were stained for 1 hr on ice with
anti-CD3 and anti-CD28 mAb (42), and anti-CD69 mAb
(provided by S. M. Fu, University of Virginia) (43), at a final
concentration of 10 pg/ml and CD40Ommunoglobulin fusion
protein (27) at a final concentration of 25 pg/ml. A murine-
human chimeric antibody (cL6) (44) was used as isotype-
matched control for CD40-immunoglobulin. Plates were
centrifuged at 1000 rpm for 3 min. The medium was aspirated,
and the cells were washed once with staining medium and
resuspended in staining medium containing either fluoresce-
in-conjugated goat anti-mouse or goat anti-human antibodies
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FIG. 1. Box plot illustration of gp39 mRNA expression, deter-
mined by RNA blot analysis, at 6 hr by PHA/PMA-activated
lymphocytes from CVI patients and matched normal controls. gp39
expression by activated lymphocytes from CVI patients, as a group,
is siificanty less than by lymphocytes from normal controls (P <
0.0001). %, Percentile.
(10 pg/ml, Tago) and incubated on ice for 30 min. The cells
were subsequently washed once with staining medium, and
antibody or fusion protein binding was determined by flow
cytometry (Epics C, Coulter).
Statistical Analysis. Statistical analysis, using Mann-
Whitney, Spearman rank, and stepwise logistic regression
tests, was done by using Statview IV (Abacus Concepts,
Berkeley, CA) on a Macintosh IHCi.
RESULTS
gp39 Gene Expansion. gp39 gene expression by PHA/
PMA-activated lymphocytes, assessed by quantitative den-
sitometry analysis of RNA blots, was found s y
diminished in CVI patients (n = 31) as a group compared with
normal controls (n = 32) (P < 0.0001) (Fig. 1). Activated
lymphocytes from 13 of the 31 CVI patients expressed gp39
mRNA at levels less than the normal control range (<0.26
unit). In Fig. 2 we show RNA blots from representative
patients whose activated lymphocytes expressed gp39
mRNA at levels within (Blot 1) and below (Blots 2 and 3) the
normal control range.
CDM_ Bnuw~bgl~nBinin. To determine whether the
quantity of gp39 mRNA expression correlates with mem-
brane-associated gp39 protein, we evaluated gp39 surface
expression by activated lymphocytes from five representa-
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FIG. 2. RNA blot analysis of gp39 mRNA obtained from acti-
vated lymphocytes from representative normal controls (NC) and
CVI patients with mRNA levels within (a) and below (b) normal
control range. RNA blots were probed for gp39 and CD38 chain,
which was used to correct for the levels of T-cell mRNA in each
sample. Corrected densitometry values (in units) forgp39 expression
are shown below (*). Differences in autoradiograph exposure time
account for the differences in intensity ofbands between CD38chain
and gp39 for each blot.
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Table 1. Surface expression of functional gp39 protein by activated T cells
gp39 mRNA gp39, % + CD3, % + CD69, % +
Patient level, units Pt NC Pt NC Pt NC
Normal range
EC 0.552 24 32 71 82 54 70
JC 0.493 18 12 87 70 79 75
SF 0.868 22 18 95 87 79 82
LL 0.943 28 12 80 70 74 57
BJ 0.937 40 48 86 85 82 86
Below normal range
LF 0.137 2 42 74 87 30 84
KJ 0.114 0 18 92 87 50 82
SS 0.089 3 42 63 87 70 84
RW 0.185 9 32 72 80 63 84
GB 0.051 0 40 53 89 17 85
Surface expression of functional gp39 protein by activated T cells is correspondingly normal in five
representative CVI patients with gp39 mRNA levels within normal control range and low in five
representative CVI patients with gp39 mRNA levels below normal control range (< 0.26). Expression
of CD3, found on all T cells, and CD69, expressed by activated T cells, is shown for comparison. %
+, Percentage of cells with positive binding of the respective chimeric or mAb minus binding of the
appropriate control (given in Materials and Methods). Pt, patient; NC, normal control.
tive patients selected from each ofthe two groups, those with
gp39 mRNA levels within (n = 18) and those below (n = 13)
the normal control range (Table 1). Surface expression of
functional gp39 protein by in vitro activated T cells, deter-
mined by CD40-immunoglobulin fusion protein binding,
correlated with gp39 message expression in that it was low in
patients with depressed (less than normal control range) gp39
gene expression and normal in those with normal (within
normal control range) gp39 gene expression. Expression of
another T-cell activation marker, CD69, was variable (normal
in some, depressed in others) in CVI patients whose activated
T cells had decreased gp39 expression, whereas CD69 was
normally expressed by activated T cells from all CVI patients
studied who had normal gp39 expression (Table 1). One
example each of CVI patients with either depressed (LF) or
normal (BJ) gp39 surface expression, along with their
matched normal control, is shown in Fig. 3. Considering our
earlier observations that CVI B cells proliferate and differ-
entiate normally to stimulation via CD40 (16), these results
suggest that in some CVI patients a T-cell defect resulting in
abnormal gp39 expression, rather than an intrinsic B-cell
defect, may play an important role in B-cell dysfunction.
Statistical Analysis Comparing gp39 Gene Expression with
CVI Patient Characteristics and Activated T-CeUl Lymphokine
Production. gp39 gene expression by activated T cells from
CVI patients significantly correlated with CD4/CD8 ratio (P
< 0.001, r = 0.6) (Fig. 4a) but not with absolute CD4 number
(P = 0.7) or absolute lymphocyte count (P = 0.09). There was
no correlation between gp39 gene expression and immuno-
globulin levels at diagnosis, patient age, or sex. In prior
studies we explored in vitro lymphokine production by
PHA/PMA-activated lymphocytes from the same patient
population (15). Comparison of gp39 gene expression with
gene expression and production of the T-cell-derived lym-
phokines evaluated (IL-2, interferon y, IL-4, IL-6, and IL-2
receptor) revealed that gp39 mRNA levels significantly cor-
related with IL-2 mRNA levels (P < 0.002, r = 0.6) (data not
shown) and with IL-2 production (P < 0.001, r = 0.7) (Fig.
4b), determined by cytotoxic T-lymphocyte cell line bioassay
but not with any of the other lymphokines evaluated. Step-
wise regression analysis with gp39 mRNA level as the
dependent variable and CD4/CD8 ratio and IL-2 production
as the independent variables revealed that IL-2 production
had the highest correlation (partial F ratio was significant at
P < 0.05). gp39 expression was less than normal control
range in the CVI patients who exhibited deficiencies of other
lymphokines (interferon yor IL-4 or both) in addition to IL-2.
DISCUSSION
The finding that CVI B cells respond in vitro to stimulation
with anti-CD40 and IL-10 or IL-4 (16) and that T cells from
a subgroup of CVI patients if stimulated in vitro fail to
produce adequate amounts of lymphokines (15) suggested to
us that T-cell dysfunction resulting in depressed or inade-
quate contact-mediated B-cell activation may play a role in
the failure of CVI B cells to differentiate appropriately into
immunoglobulin-secreting plasma cells. To test this hypoth-
esis, we took advantage of the recent identification of a
receptor-ligand pair, CD40/gp39, shown to be important in T
cell-B cell communication. mAb (17, 18, 20) and ligand-
binding (28, 30, 31) experiments have shown that gp39-CD40
interaction plays a central role in B-cell proliferation, differ-
entiation, and isotype switching. Anti-CD40 mAb (21-25),
gp39-expressing fibroblasts (28, 30, 31), or soluble gp39
construct (30) in the presence of IL-4 can induce B cells to
proliferate and produce IgE. Anti-CD40 mAb (16, 26) and
soluble gp39 construct (45) in the presence of IL-10 can drive
gp39 CD69 CD3
LF
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FIG. 3. gp39 surface expression by activated T cells is corre-
spondingly decreased in a representative patient (LF) with depressed
gp39 mRNA expression and normal in a representative patient (BJ)
with normal gp39 mRNA expression. NC, matched normal control.
Peripheral blood mononuclear cells were stimulated in vitro and
stained, as described, with either CD40-immunoglobulin, CD69
mAb, or CD3 mAb (solid line) and a murine-human chimeric anti-
body (cL6) or goat anti-mouse antibody as controls for nonspecific
binding (dashed line).
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FIG. 4. (a) T-cell CD4/CD8 ratio significantly correlates with gp39 mRNA expression level, determined by RNA blot analysis, by
PHA/PMA-activated lymphocytes from CVI patients (P < 0.001, r = 0.6). (b) PHA/PMA-activated CVI T-cell IL-2 production, measured by
cytotoxic T-lymphocyte cell line bioassay, and level of gp39 mRNA expression, measured by RNA blot analysis, also correlate significantly
(P < 0.001, r = 0.7). Stepwise logistic regression analysis revealed that IL-2 production correlated more highly with gp39 message expression
(P < 0.05) than with CD4/CD8 ratio.
committed B cells to differentiate into IgG-, IgA-, and
IgM-producing cells. Because CVI B cells stimulated with
anti-CD40 mAb in the presence of IL4 proliferate and
produce IgE normally (16), CD40 must be present and
functional on CVI B cells. This observation also indicates
that CVI B cells, similar to B cells from HIM patients (33),
can mature into immunoglobulin-secreting cells if appropri-
ate signals are provided, suggesting that B cells from most
CVI patients are functionally normal. Several recent reports
have shown that defective expression of functional gp39 by
activated T cells is the molecular defect responsible for B-cell
dysfunction in HIM (33-37). Considering the critical role of
CD40-gp39 interaction in B-cell activation and differentia-
tion, we examined in detail gp39 expression by activated
lymphocytes from a large group of well-characterized CVI
patients.
The levels ofgp39 mRNA expressed by activated lympho-
cytes from CVI patients as a group were significantly lower
than levels from normal control individuals and were below
the normal control range in42% ofthe patients studied. T-cell
surface expression of functional gp39 protein, determined by
binding of a soluble form of CD40 (CD40-immunoglobulin
fusion protein), was correspondingly low in patients with
reduced gp39 mRNA levels and normal in patients with
normal gp39 mRNA levels. The nucleotide sequences of
cDNAs encoding gp39 from two CVI patients, one with low
and one with normal levels of gp39 mRNA expression (33),
were identical to those reported for normal individuals (30,
31), indicating that CVI patients do not have a structurally
defective gp39 protein, in contrast with HIM patients in
which gp39 protein is structurally abnormal or absent (33-
36). These data suggest that CVI patients with depressed
gp39 expression by activated T cells, regardless of the
underlying primary defect, may have abnormal in vivo anti-
body responses due to inefficient signaling via the B-cell
surface receptor CD40.
CVI is a heterogeneous group of disorders that have in
common a B-cell-differentiation defect, resulting in hypogam-
maglobulinemia and antibody deficiency. To explain the
pathophysiologic basis for CVI, several mechanisms were
proposed, including intrinsic B-cell abnormalities (3, 7, 8),
the presence ofT-suppressor cells (9-11), or abnormal T-cell-
mediated B-cell help involving T-cell-derived lymphokines
(12-15). The results of this study suggest that suboptimal
T-cell contact-mediated B-cell help via gp39-CD40 interac-
tion, due to the depressed expression ofgp39 by activated T
cells, may contribute to the failure of B-cell differentiation
and abnormal in vivo antibody responses in at least a sub-
group of CVI patients. gp39-CD40 interaction is critical for
isotype switching and clonal expansion, as demonstrated by
its absence in patients with HIM. When immunized with the
T-dependent antigen bacteriophage qX174, affected males
with HIM have depressed antiphage antibody titer during
both the prinmary and secondary responses and fail to switch
from IgM to IgG isotype (45). The CVI patients included in
this study all had significantly depressed production of an-
tiphage antibody during the primary and secondary responses
as well but differed in their ability to switch from IgM to IgG
isotype. Most patients, 10 of 13 and 11 of 18 with depressed
and normal gp39 expression, respectively, were unable to
appropriately switch from IgM to IgG isotype during the
secondary response. Potentially, a number of factors may be
contributing to the observed B-cell dysfunction in these
patients, including suboptimal signaling via gp39-CD40, an
intrinsic B-cell defect or inadequate T-cell-derived costimu-
latory signals.
A number ofdifferent underlying molecular defects may be
responsible for depressed gp39 expression by activated CVI
T cells. Abnormally low gp39 expression may result from
defective transcription or message stability of gp39, which,
depending on the extent of the primary defect, may affect
expression of one or more lymphokine(s) or other activation
molecules as well. The hypothesis of variable T-cell defects
in a subgroup ofCVI patients is supported by the finding that
activated lymphocytes from most CVI patients evaluated had
depressed production of one or more T-cell-derived lympho-
kines (15). Further evidence for a broader T-cell defect in
some patients is supported by the observations that de-
creased IL-2 production significantly correlated with de-
pressed gp39 expression, that all patients with multiple
lymphokine deficiency exhibited depressed gp39 expression
as well, and that in some patients with poor gp39 surface
expression, expression of another activation marker, CD69,
was also decreased. The association between IL-2 and gp39
gene expression suggests that these two genes may share
transcription regulation factor(s) that may be dysfunctional in
a subset of CVI patients. Because CD4/CD8 ratio also
correlated, but was not as predictive as IL-2 production as
a
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determined by stepwise regression, with level of gp39 mes-
sage expression, it follows that both may be regulated in such
a way that they are predominately produced by CD4+ T cells.
Our CVI patient population can be divided into two groups
based on T-cell function assessed by lymphokine production
and CD40 ligand expression. In our studies, 74% (23/31
patients) of the patients exhibit a T-cell defect, whereas the
remaining 26% (8/31 patients) do not. Patients with T-cell
dysfunction can be further subdivided into those with a
broader defect (n = 11), resulting in depressed gp39 expres-
sion and variable lymphokine deficiency and those with a
more selective defect of either CD40 ligand expression (n =
2) or deficiency of one particular lymphokine (n = 10). We
postulate that CVI arises from a number of different molec-
ular aberrations that may include intrinsic B-cell abnormal-
ities, broader defects ofT- and/or B-cell activation, and more
selective T-cell defects, resulting in abnormal expression of
a particular surface molecule or lymphokine leading to dys-
functional B-cell proliferation, maturation, and/or differen-
tiation. Further characterization of T- and B-cell function in
these patients will eventually lead to the elucidation of the
primary defects and point to additional diagnostic and ther-
apeutic interventions for these patients, as well as contribute
to our understanding of the workings of the immune system.
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